Viking Therapeutics reports Q3 results October 28 after launching oral VK2735 Phase 3
The company started its SUNRISE program for oral VK2735 on October 14 and closed an upsized $500 million raise priced at $35.00 per share.
TR
By Tom Reyes · Markets Editor
Oct 25 11:47 ETSource: 24/7 Wall St.
The wire
- 01Viking reports third-quarter results on October 28, 2026, after a $128.02 million net loss last quarter, $115.75 million in R&D spending and cash falling to $502 million from $706 million.
- 02Oral VK2735 is positioned as a dual GLP-1/GIP agonist; Phase 2 VENTURE-Oral showed up to 12.2% mean weight loss at 13 weeks, and maintenance patients kept 90% to 97% of lost weight.
- 03This is an investor preview, not company guidance; spending will rise as SUNRISE runs alongside VANQUISH-1 and VANQUISH-2, which enroll roughly 5,500 patients. Shares are down 30.64% year to date.
From the source
Read at 247wallst.comWhy Viking Therapeutics’ Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics reports earnings on October 28 with shares down over 41% in a month and a newly launched oral obesity trial demanding answers from management. What happens on this call could flip the narrative or confirm investors' worst fears.
